Abstract:Resistance to key first-line drugs is a major hurdle to achieve the global end tuberculosis (TB) targets. A prodrug, pyrazinamide (PZA) is the only drug, effective in latent TB, recommended in drug resistance and susceptible Mycobacterium tuberculosis (MTB) isolates. The prodrug conversion into active form, pyrazinoic acid (POA), required the activity of pncA gene encoded pyrazinamidase (PZase). Although pncA mutations have been commonly associated with PZA resistance but a small number of resistance cases have been associated with mutationss in RpsA protein. Here in this study a total of 69 PZA resistance isolates have been sequenced for pncA mutations. However, samples that were found PZA resistant but pncA wild type ( pncA WT ), have been sequenced for rpsA and panD genes mutation. We repeated a drug susceptibility testing according to the WHO guidelines on 18 pncA WT MTB isolates. The rpsA and panD genes were sequenced. Out of total 69 PZA resistant isolates, 51 harbored 36 mutations in pncA gene (GeneBank Accession No. MH46111) while, fifteen different mutations including seven novel, were detected in the fourth S1 domain of RpsA known as C-terminal (MtRpsA CTD ) end. We did not detect any mutations in panD gene. Among the rpsA mutations, we investigated the molecular mechanism of resistance behind mutations, D342N, D343N, A344P, and I351F, present in the MtRpsA CTD through molecular dynamic simulations (MD). WT showed a good drug binding affinity as compared to mutants (MTs), D342N, D343N, A344P, and I351F. Binding pocket volume, stability, and fluctuations have been altered whereas the total energy, protein folding, and geometric shape analysis further explored a significant variation between WT and MTs. In conclusion, mutations in MtRpsA CTD might be involved to alter the RpsA activity, resulting in drug resistance. Such molecular mechanism behind resistance may provide a better insight into the resistance mechanism to achieve the global TB control targets.

Structural Insights of Catalytic Mechanism in Mutant Pyrazinamidase of Mycobacterium Tuberculosis.

Insights into the Mechanisms of the Pyrazinamide Resistance of Three Pyrazinamidase Mutants N11K, P69T, and D126N.

Structural dynamics behind clinical mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis associated with pyrazinamide resistance

Pyrazinamide resistance and mutations L19R, R140H, and E144K in Pyrazinamidase of Mycobacterium tuberculosis.

Insights Into Mutations Induced Conformational Changes and Rearrangement of Fe2+ Ion in pncA Gene of Mycobacterium tuberculosis to Decipher the Mechanism of Resistance to Pyrazinamide

Mechanistic analysis of A46V, H57Y, and D129N in pyrazinamidase associated with pyrazinamide resistance

Free Energy Landscape and Thermodynamics Properties of Novel Mutations in PncA of Pyrazinamide Resistance Isolates of Mycobacterium Tuberculosis

Pyrazinamide Resistance of Novel Mutations Inpncaand Their Dynamic Behavior

Insight into Novel Clinical Mutants of RpsA-S324F, E325K, and G341R of Mycobacterium Tuberculosis Associated with Pyrazinamide Resistance

Drug resistance mechanism of PncA in Mycobacterium tuberculosis

Thermodynamics Properties of L120R Mutant Pyrazinamidase and Pyrazinamide Resistance

Identification of Novel Mutations in LprG (rv1411c), Rv0521, Rv3630, Rv0010c, Ppsc, Cyp128 Associated with Pyrazinoic Acid/pyrazinamide Resistance in Mycobacterium Tuberculosis

Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide.

Mechanistic Insights into the Conformational Changes and Alterations in Residual Communications Due to the Mutations in the pncA Gene of Mycobacterium tuberculosis : A Computational Perspective for Effective Therapeutic Solutions

Studying the dynamics of the drug processing of pyrazinamide in Mycobacterium tuberculosis

Pyrazinoic Acid Inhibits the Bifunctional Enzyme (rv2783) in Mycobacterium Tuberculosis by Competing with Tmrna

Aspartate Decarboxylase (pand) As a New Target of Pyrazinamide in Mycobacterium Tuberculosis.

Mutations in Pand Encoding Aspartate Decarboxylase Are Associated with Pyrazinamide Resistance in Mycobacterium Tuberculosis

Pyrazinamide Inhibits Trans-Translation in Mycobacterium Tuberculosis

Structural and free energy landscape of novel mutations in ribosomal protein S1 (rpsA) associated with pyrazinamide resistance

Insight to the molecular mechanisms of the osmolyte effects on Mycobacterium tuberculosis pyrazinamidase stability using experimental studies, molecular dynamics simulations, and free energy calculation